Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines

British Journal of Cancer

Volumn 102, Issue 1, 2010, Pages 173-180

  Mallett, S ^a   Timmer, A ^b,c   Sauerbrei, W ^c   Altman, D G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Prognostic; REMARK; Reporting guideline; Survival analysis; Tumour marker

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; SYSTEMATIC REVIEW;

GUIDELINES AS TOPIC; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENT SELECTION; PROGNOSIS; PUBLISHING; RESEARCH DESIGN; SELECTION BIAS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WRITING;

EID: 74249084720     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605462     Document Type: Article

References (41)

1. Altman DG (2006) Studies investigating prognostic factors: Conduct and evaluation. In Prognostic Factors in Cancer Gospodarowicz MK, O'Sullivan B, Sobin LH (eds) 3rd edn, pp 39-54. John Wiley & Sons: New York
2. Altman DG (2007) Prognostic models: a methodological framework and review of models for breast cancer. In Breast cancer. Translational therapeutic strategies Lyman GH, Burstein HJ (eds) pp 11-25. Informa Healthcare: New York.
3. Healthcare: New York Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518
4. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
5. Altman DG, Riley RD (2005) Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2: 466-472
6. Barth J, Schumacher M, Herrmann-Lingen C (2004) Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 66: 802-813
7. Bentzen SM (2001) Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 49: 513-518
8. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057
9. Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91: 4-8
10. Clark TG, Altman DG, De Stavola BL (2002) Quantification of the completeness of follow-up. Lancet 359: 1309-1310
11. De Azambuja E, Cardoso F, de Jr CG., Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504-1513
12. Faraggi D, Kramar A (2000) Methodological issues associated with tumor marker development. Biostatistical aspects. Urol Oncol 5: 211-213
13. Gasparini G (1998) Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat 52: 321-331 (Pubitemid 29056103)
14. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12: 473-477
15. Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437
16. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA (2002) Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 12: 1-6
17. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW (2006) Selenium binding protein 1 in ovarian cancer. Int J Cancer 118: 2433-2440
18. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25: 2127-2132
19. Infante-Rivard C, Villeneuve JP, Esnaola S (1989) A framework for evaluating and conducting prognostic studies: an application to cirrhosis of the liver. J Clin Epidemiol 42: 791-805
20. Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM (2004) Systematic review of prognostic cohort studies on shoulder disorders. Pain 109: 420-431
21. Kyzas PA, Cunha IW, Ioannidis JP (2005a) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11: 1434-1440
22. Kyzas PA, Loizou KT, Ioannidis JP (2005b) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97: 1043-1055
23. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007a) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43: 2559-2579
24. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007b) Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99: 236-243
25. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6: 678-686
26. Marx BE, Marx M (1997) Prognosis of idiopathic membranous nephro-pathy: a methodologic meta-analysis. Kidney Int 51: 873-879
27. McShane LM, Altman DG, Sauerbrei W (2005a) Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97: 1023-1025
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005b) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391 (Pubitemid 43080010)
29. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357: 1191-1194 (Pubitemid 32378696)
30. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du BA, Kiechle-Schwarz M, Pfleiderer A (1994) Cellular DNA content and survival in advanced ovarian carcinoma. Cancer 74: 2509-2515
31. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Altman DG (2006) Where next for evidence synthesis of prognostic marker studies? Improving the quality and reporting of primary studies to facilitate clinically relevant evidence-based results. In Advances in Statistical Methods for the Health Sciences Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G (eds) Chapter 3, pp 40-58. Birkhauser and Springer: Boston
32. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA (2003) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88: 1191-1198
33. Riley RD, Sauerbrei W, Altman DG (2009) Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100: 1219-1229
34. Sauerbrei W (2005) Prognostic factors: confusion caused by bad quality design, analysis and reporting of many studies. In Current Research in Head and Neck Cancer. Advances in Oto-Rhino-Laryngology, Bier H (ed), Vol.62 pp 184-200. Karger: Basel.
35. Sauerbrei W, Holländer N, Riley RD, Altman DG (2006) Evidence based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Communs Stat Theory Methods 35: 1333-1342
36. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346
37. Scholten-Peeters GG, Verhagen AP, Bekkering GE, van der Windt DA, Barnsley L, Oostendorp RA, Hendriks EJ (2003) Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain 104: 303-322
38. Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J (2009) Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess 13: iii, xi-iiixiii
39. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA (2006) Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 107: 90-98
40. Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML (2006) Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. J Clin Oncol 24: 1627-1632
41. Whiteley W, Chong WL, Sengupta A, Sandercock P (2009) Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40: e380-e389